missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CDw293 Monoclonal Antibody (06)

Description
This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%). This antibody has specificity for Human ALK-6/BMPR1B.
BMPR1B (also known as ALK6, CDw293) is a member of the transmembrane serine/threonine kinase that is the member of the bone morphogenetic protein (BMP) receptor, which is closely related to the activin receptors, ACVR1 and ACVR2. BMPR1B is mainly involved in the endochondral bone formation and embryogenesis. BMPR1B expressed in normal and cancerous prostate tissues and used in the endocrine therapy that given to the prostate cancer patients. BMPR1B receptor trafficking also play a significant role in FOP pathogenesis and used in human T-cell differentiation.
Specifications
Specifications
| Antigen | CDw293 |
| Applications | ELISA |
| Classification | Monoclonal |
| Clone | 06 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with no preservative |
| Gene | BMPR1B |
| Gene Accession No. | O00238 |
| Gene Alias | Activin receptor-like kinase 6; Acvrlk6; AI385617; Alk6; ALK-6; AMDD; AV355320; BDA1D; BDA2; BMP type-1B receptor; BMP15; Bmpr1b; BMPR-1B; BMPRIB; BMPR-IB; bone morphogenetic protein binding serine/threonine kinase receptor; bone morphogenetic protein receptor IB; bone morphogenetic protein receptor type 1B; bone morphogenetic protein receptor type IB; bone morphogenetic protein receptor type-1B; bone morphogenetic protein receptor, type 1B; bone morphogenetic protein receptor, type IB; CDw293; CFK-43a; serine/threonine receptor kinase; serine/threonine-protein kinase receptor R6; SKR6 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?